Literature DB >> 26622999

Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.

Smith Giri1, Ranjan Pathak2, Mike G Martin1, Vijaya Raj Bhatt3.   

Abstract

Entities:  

Year:  2015        PMID: 26622999      PMCID: PMC4649605          DOI: 10.1177/2040620715607416

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN: 2040-6207


× No keyword cloud information.
  13 in total

1.  Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.

Authors:  Juan L Garcia; Jaime Font de Mora; Jesus M Hernandez; Jose A Queizan; Norma C Gutierrez; Jose M Hernandez; Jesus F San Miguel
Journal:  Blood       Date:  2003-10-01       Impact factor: 22.113

2.  Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique.

Authors:  P Martiat; J L Michaux; J Rodhain
Journal:  Blood       Date:  1991-07-01       Impact factor: 22.113

3.  Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia.

Authors:  M Koldehoff; N K Steckel; Y Hegerfeldt; M Ditschkowski; D W Beelen; A H Elmaagacli
Journal:  Int J Lab Hematol       Date:  2011-06-27       Impact factor: 2.877

4.  Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

Authors:  Carlo B Gambacorti-Passerini; Carla Donadoni; Andrea Parmiani; Alessandra Pirola; Sara Redaelli; Giovanni Signore; Vincenzo Piazza; Luca Malcovati; Diletta Fontana; Roberta Spinelli; Vera Magistroni; Giuseppe Gaipa; Marco Peronaci; Alessandro Morotti; Cristina Panuzzo; Giuseppe Saglio; Emilio Usala; Dong-Wook Kim; Delphine Rea; Konstantinos Zervakis; Nora Viniou; Argiris Symeonidis; Heiko Becker; Jacqueline Boultwood; Leonardo Campiotti; Matteo Carrabba; Elena Elli; Graham R Bignell; Elli Papaemmanuil; Peter J Campbell; Mario Cazzola; Rocco Piazza
Journal:  Blood       Date:  2014-10-24       Impact factor: 22.113

5.  Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.

Authors:  J M Hernández; M C del Cañizo; A Cuneo; J L García; N C Gutiérrez; M González; G Castoldi; J F San Miguel
Journal:  Ann Oncol       Date:  2000-04       Impact factor: 32.976

6.  BCR rearrangement-negative chronic myelogenous leukemia revisited.

Authors:  R Kurzrock; C E Bueso-Ramos; H Kantarjian; E Freireich; S L Tucker; M Siciliano; S Pilat; M Talpaz
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

Review 7.  The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Authors:  Jason Gotlib; Julia E Maxson; Tracy I George; Jeffrey W Tyner
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

8.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

9.  Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.

Authors:  P Mittal; R M Saliba; S A Giralt; M Shahjahan; A I Cohen; S Karandish; F Onida; M Beran; R E Champlin; M de Lima
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

10.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

View more
  8 in total

Review 1.  Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Authors:  Andrew T Kuykendall; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

3.  Characteristics and survival of patients with atypical chronic myeloid leukemia.

Authors:  Jee Hyun Kong; Hohyung Nam; Tae-Hwa Go; Shin Young Hyun; Kwang Yong Shim
Journal:  Blood Res       Date:  2019-09-25

4.  Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia.

Authors:  Carmela Gómez; Rósula Garcia-Navas; Fernando C Baltanás; Rocío Fuentes-Mateos; Alberto Fernández-Medarde; Nuria Calzada; Eugenio Santos
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

5.  Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.

Authors:  Tumas Beinortas; Ilma Tavorienė; Tadas Žvirblis; Rolandas Gerbutavičius; Mindaugas Jurgutis; Laimonas Griškevičius
Journal:  BMC Cancer       Date:  2016-03-08       Impact factor: 4.430

6.  Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.

Authors:  Zhimin Tan; Aixia Peng; Jingwen Xu; Mingwen Ouyang
Journal:  BMC Anesthesiol       Date:  2017-09-29       Impact factor: 2.217

7.  Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada.

Authors:  Leonard Tu Nguyen; Maggie Guo; Christopher Naugler; Fariborz Rashid-Kolvear
Journal:  BMC Res Notes       Date:  2018-11-01

Review 8.  Atypical Chronic Myeloid Leukemia: Where Are We Now?

Authors:  Elena Crisà; Maura Nicolosi; Valentina Ferri; Chiara Favini; Gianluca Gaidano; Andrea Patriarca
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.